FDA Ratchets Up Overseas Inspections For FY 2010 - 924 For Drug Activities
Executive Summary
FDA expects to increase its oversight of overseas pharmaceutical company activities by one-third in fiscal 2010 as it doubles the total number of foreign inspections it conducts
You may also be interested in...
High-Risk Drug Imports To Be Delayed, FDA PREDICTs; Focus On Data Quality Can Avoid New 20 Percent Dragnet
An FDA information technology system designed to identify high-risk imports for possible inspection should speed U.S. entry for about 80 percent of FDA-regulated products coming into the country
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials